12:03 PM
 | 
Mar 20, 2019
 |  BC Extra  |  Clinical News

Cytokinetics gets bump after DMC says CVOT should proceed

Editor's Note: This article was updated on Mar 21, 2019 at 10:40 AM PDT

Cytokinetics added $1.63 (19%) to $10.19 on Wednesday after it said a DMC recommended the Phase III GALACTIC-HF cardiovascular outcomes trial of omecamtiv mecarbil continue without changes following a planned interim analysis, which included a prespecified futility analysis. The trial is evaluating the cardiac myosin activator...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >